https://www.selleckchem.com/products/cc-122.html
The aim of this study was to investigate the effectiveness of SGLT2 inhibitors with regard to metabolic parameters and patient safety under routine ambulatory conditions. Retrospective longitudinal study of 95 patients with type 2 diabetes (diabetes duration 13.3 y; HbA1c 8.9%; eGFR 80.1 mL/min) receiving SGLT-2-inhibitors. Metabolic control and adverse event profile were evaluated. The mean follow-up time was 1.2 ± 0.8 years. The following changes were observed HbA1c -1.0% ± 1.9 (p less then 0.001), eGFR -7.0 mL/min ± 13.3 (p less then
Like
Comment
Share
